


RESEARCH

Open Access



Selections, frameshift mutations, and copy number variation detected on the *surf*_{4.1} gene in the western Kenyan *Plasmodium falciparum* population

Jesse N. Gitaka^{1,2,3}, Mika Takeda², Masatsugu Kimura⁴, Zulkarnain Md Idris^{5,6}, Chim W. Chan⁵, James Kongere⁷, Kazuhide Yahata^{1,2}, Francis W. Muregi³, Yoshio Ichinose^{1,7}, Akira Kaneko^{5,8,9} and Osamu Kaneko^{1,2*} 

Abstract

Background: *Plasmodium falciparum* SURFIN_{4.1} is a putative ligand expressed on the merozoite and likely on the infected red blood cell, whose gene was suggested to be under directional selection in the eastern Kenyan population, but under balancing selection in the Thai population. To understand this difference, *surf*_{4.1} sequences of western Kenyan *P. falciparum* isolates were analysed. Frameshift mutations and copy number variation (CNV) were also examined for the parasites from western Kenya and Thailand.

Results: Positively significant departures from neutral expectations were detected on the *surf*_{4.1} region encoding C-terminus of the variable region 2 (Var2) by 3 population-based tests in the western Kenyan population as similar in the Thai population, which was not covered by the previous analysis for eastern Kenyan population. Significant excess of non-synonymous substitutions per nonsynonymous site over synonymous substitutions per synonymous site was also detected in the Var2 region. Negatively significant departures from neutral expectations was detected on the region encoding Var1 C-terminus consistent to the previous observation in the eastern Kenyan population. Parasites possessing a frameshift mutation resulting a product without intracellular Trp-rich (WR) domains were 22/23 in western Kenya and 22/36 in Thailand. More than one copy of *surf*_{4.1} gene was detected in western Kenya (4/24), but no CNV was found in Thailand (0/36).

Conclusions: The authors infer that the high polymorphism of SURFIN_{4.1} Var2 C-terminus in both Kenyan and Thai populations were shaped-up by diversifying selection and maintained by balancing selection. These phenomena were most likely driven by immunological pressure. Whereas the SURFIN_{4.1} Var1 C-terminus is suggested to be under directional selection consistent to the previous report for the eastern Kenyan population. Most western Kenyan isolates possess a frameshift mutation that would limit the expression of SURFIN_{4.1} on the merozoite, but only 60% of Thai isolates possess this frameshift, which would affect the level and type of the selection pressure against this protein as seen in the two extremities of Tajima's *D* values for Var1 C-terminus between Kenyan and Thai populations. CNV observed in Kenyan isolates may be a consequence of this frameshift mutation to increase benefits on the merozoite surface.

Keywords: Copy number variation, Frameshift, Malaria, *Plasmodium falciparum*, Selection, SURFIN_{4.1}

*Correspondence: okaneko@nagasaki-u.ac.jp

² Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
Full list of author information is available at the end of the article

Background

Malaria poses a serious public health challenge causing estimated 438,000 deaths and 214 million clinical cases in 2015, especially in sub-Saharan Africa where the dominant species is *Plasmodium falciparum* [1]. In human hosts, *P. falciparum* multiplies in the red blood cell (RBC), where malaria pathogenicity is mediated by parasite-encoded proteins expressed on the RBC invasive merozoite stage parasite and parasite-infected RBC surface. Therefore, parasite proteins that interact with the host RBCs and endothelial cells are potential immune targets and may serve as vaccine candidates for intervention.

A large type 1 transmembrane protein SURFIN encoded by a surface-associated interspersed gene (*surf* gene) family has a unique position in such proteins, because its extracellular Cys-rich domain (CRD) and intracellular Trp-rich (WR) domain have homology with a variety of adhesins expressed on the surface of the RBC infected by not only *P. falciparum* but also other *Plasmodium* species, for example, CRD with PIR proteins encoded by the *Plasmodium* interspersed repeats (*pir*) super multigene family in primate and rodent malaria parasites and WR with *P. falciparum* PfEMP1 and *Plasmodium knowlesi* SICAvAr [2], suggesting SURFIN components were utilized to generate lineage-specific adhesins expressed on the iRBC surface through domain shuffling with other proteins. These shared structural components point to an evolutionary basal position and important roles of SURFIN in the parasite–host interaction. *P. falciparum* SURFIN_{4.1} is proposed to be involved in the reversible association with target RBCs when it is located on the merozoite surface [3]. Furthermore, exogenously expressed partial SURFIN_{4.1} in *P. falciparum* was observed to be transported to the iRBC [4], suggesting that this protein is potentially also expressed on the iRBC surface as its paralog SURFIN_{4.2} [2]. Interestingly, in *P. falciparum* 3D7 and MS822 lines, SURFIN_{4.1} is truncated just after the transmembrane region due to a premature stop codon caused by a frameshift mutation. Conversely, in another line FCR3, this frameshift mutation does not occur and SURFIN_{4.1} contains two WR domains in the intracellular region [4]. Moreover, the sequence of IT line *P. falciparum* in the PlasmoDB database (PFIT_0400900) does not possess these frameshifts and the protein product is expected to contain three WR domains similar to SURFIN_{4.2} (Fig. 1). Since the intracellular region containing WR domain has an important role for the iRBC surface expression in the case of SURFIN_{4.2} [5], SURFIN_{4.1} would be expressed on the iRBC surface only by *P. falciparum* isolates possessing WR domain. SURFIN_{4.1} variants without WR domain would be expressed only on the merozoite surface. The abundance of such type

of SURFIN_{4.1} would affect the evolutionary process and diversity as the exposure times to the host immune system are very different (>24 h on the iRBC surface versus up to several minutes on the merozoite surface). Optimal specificity and strength of the putative SURFIN_{4.1}-host receptor interactions, although not proved yet, would be different (iRBC-endothelial cells/RBC versus merozoite-RBC). Copy number variation (CNV) was also reported for *surf*_{4.1}, but its biological significance is not known [2].

Population genetic approaches offer an avenue to study the effect of acquired immune responses on pathogen genetic polymorphism [6]. This strategy that involves study of nucleotide diversity for signatures of selection on particular antigens has unveiled candidate vaccine targets such as AMA1 [7–9], MSP1 [10], MSP2 [11, 12], MSP3 [13], EBA175 [14] and SURFIN_{4.2} [15] among others. *surf*_{4.1} gene region encoding SURFIN_{4.1} extracellular region possesses more polymorphic sites than the corresponding region of the *surf*_{4.2} gene. Significant positive deviations of Tajima's *D* value from zero were detected on *surf*_{4.2} in both Thai and Kenyan parasite populations and positive selection was proposed on this gene [15, 16]. However, this is not the case for *surf*_{4.1}, for which positively deviated Tajima's *D* values were detected in Thai *P. falciparum* population [17], but negatively deviated values in the parasite population from Ngerenye area of Kilifi, eastern Kenya [15]. To gain insights on the cause of this difference, the authors determined *surf*_{4.1} gene sequences in the western Kenyan *P. falciparum* population and evaluated allelic diversity, the type of selection pressure, frameshift mutations, and copy number variation.

Methods

Parasite collection and DNA extraction

Twenty-three *P. falciparum* isolates obtained in the Lake Victoria islands of Kibuogi, Ngodhe, Takawiri and the shore village of Ungoye in Kenya in August 2014 [18] were adapted to the in vitro culture basically as described previously [19]; briefly, in RPMI-1640 medium containing 10% heat-inactivated pooled type AB⁺ human serum, 200 mM hypoxanthine, 20 µg/mL gentamicin and O⁺ human RBC at 2% hematocrit. Human erythrocytes and plasma used for the culture were obtained from Nagasaki Red Cross Blood Center. The sampling was authorized by the Ethical Review Committee of University of Nairobi and Kenyatta National Hospital and carried out in accordance with the approved guidelines. After a short period of culture (≤15 days, median 7 days), genomic DNA (gDNA) were extracted from the parasites using QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instruction. Four isolates were cloned by limiting dilution before DNA extraction to

determine the sequence encoding SURFIN_{4.1} (Gene ID PF3D7_0402200) extracellular region. To further analyse the frameshifts and CNV for the western Kenya parasites, DNA was obtained after cloning. For the cloned parasites, it took up to 40 days from starting culture to extracting DNA.

To evaluate the frameshifts and CNV of *surf*_{4.1} in Thai *P. falciparum* isolates, genomic DNA from 25 isolates and 3 clones prepared previously was used and showed clear single peaks for *surf*_{4.1} sequence [17]. The following Thai isolates were newly cloned before DNA extraction to avoid potential problems caused by the infection of more than one allele; MS807-H3, MS814-F1, MS815-A2, MS818-C2, MS819-A3, MS829-B5, MS833-B4, and MS844-A4.

Polymerase chain reaction (PCR) amplification and sequencing

For 23 Kenyan samples (KK14-2, KK14-53, KK14-92, KN14-076, KN14-98, KT14-111, KT14-158, KU14-42, KU14-44, KU14-50, KU14-061, KU14-62, KU14-71, KU14-86, KU14-110, KU14-119, KU14-127, KU14-170, KU14-175, KU14-211, KU14-217, KU14-226, and KU14-257), DNA fragments for *surf*_{4.1} (PF3D7_0402200) encoding extracellular region were amplified with the following conditions; an initial denaturation step of 94 °C for 2 min followed by 40 amplification cycles of 98 °C for 10 s, 50 °C for 30 s, and 68 °C for 90 s, then final extension step of 68 °C for 5 min. Reaction was performed in a 12.5-μL reaction mixture containing 200 μM dNTP, 0.4 units of KOD-Plus NEO DNA polymerase (Toyobo, Japan), 2.0 μL of 10× KOD-Plus NEO buffer, 1.5 mM MgSO₄, 0.4 μL of the template DNA solution, and 0.3 μM each of forward (F4.1, AAAGTTTATTAAACCAGAAATGTAAAC, corresponding to the nucleotide positions (nt) -91 to -64) and reverse (R4.1, ATTACTTTGT-TAAATAATATAAAAACG, nt 2375–2349) primers. PCR products were subjected to a 1.5% agarose gel electrophoresis and visualized with ethidium bromide under UV transillumination. Negative control reaction was always set using distilled water as a template solution. DNA standard marker was used to evaluate the size of the PCR products.

When the PCR band on the agarose gel was confirmed to be single with least or no background, amplified DNA fragments were treated with ExoSAP-IT (GE Healthcare, Buckinghamshire, UK) and sequenced directly with ABI PRISM® BigDye™ Terminator ver1.1 using a panel of oligonucleotide primers as described before [17] according to the manufacturer's instruction. Sequences were then analysed with an ABI3730 DNA analyzer (Applied Biosystems, Foster City, CA). The sample with multiple peaks in chromatogram, indicating a

mixed allele infection, were sequenced after cloning of the PCR-amplified DNA fragment into pGEM®-T Easy (Promega, Madison WI) (KT14-111-T1, KU14-119-T1, KU14-119-T2) or sequencing was performed from the PCR products obtained from parasite lines after parasite cloning (KN14-076-B6, KT14-158-G3, KU14-061-B1, and KU14-257-A7). Sequences supported by at least two independent plasmid clones were employed. One isolate (KU14-119) yielded 2 distinct *surf*_{4.1} sequences (KU14-119-T1 and KU14-119-T2) that were supported by 2 and 4 independent plasmid clones, respectively.

To determine the existence of a frameshift at nt 2498–2503 in the *surf*_{4.1} gene encoding the region adjacent to the transmembrane region, PCR products were amplified with one of forward primers (F6, GATG-GACTTAATGGATTGATC, nt 1708–1729; F6_7G8, GATGAAAACGATGCATTTGTTTC, nt 1708–1729; F6_HB3, TGATGAAAACAATGGATTTGTTTC, nt 1707–1729; or F6_842, GTGGATAACTATGCATTTGTTTC, nt 1708–1729) and a reverse primer (R1, TTA-TATCTTCTTTTCAAACTTCATC, nt 2728–2701), and sequenced with R1 and R4.1. For some parasites, PCR products were amplified with F6 and R10 (CCAAACAT-ATATCCAAAATGTGCTC, nt 3520–3495), and sequenced with R10 and R11 (CCAACATTCTCCCTT-GTCCATC, nt 2950–2929). To examine the other two frameshifts at nt 3894–3903 and 4529–4536 in the intracellular region, PCR products were amplified with primers F2 (GAAAAAGGATATTCCCATAAAACATTG, nt 2929–2950) and WR.R2 (CATTGCTATTTTAAACCAATCTG, nt 4891–4869) and sequenced with R2 and WR.R2.

Quantitative real-time PCR (qPCR)

Copy number variation of *surf*_{4.1} gene was examined by the comparative C_T method using *ama1* gene as a control gene locus, for which CNV has not been noted. qPCR for *surf*_{4.1} was performed with the following conditions; an initial denaturation step of 95 °C for 10 min followed by 50 amplification cycles of 95 °C for 15 s, 45 °C for 20 s, and 62 °C for 1 min. Reactions were performed using Power SYBR Green Master Mix (Applied Biosystems) with primers PFD0100c.rtF2 (TAAGAACA-GAACATAATTATGATAA, nt 308–332) and PFD0100c.rtR1 (CAATCCTGTTCTGCATATTTTATG, nt 431–409) using Applied Biosystems 7500 Fast Real-Time PCR System. qPCR for *ama1* (PF3D7_1133400) was performed as same as for *surf*_{4.1} with a slight difference; with primers fAMA1-RT.F1 (AAGACGAAAATACAT-TACAACACGCA, nt 203–228) and fAMA1-RT.R1 (CTACTCTTATACCTGAACCATGAACT, nt 388–363) and the combined annealing/extension step at 62 °C for 1 min. The quality of the PCR-amplified products were validated by the melting curve method. The amplification

efficiency of qPCR for both *surf*_{4.1} and *ama1* were determined to be 0.7 using serially diluted DNA solution of *P. falciparum* 3D7 line and used for the calculation.

Statistical analyses

Sequences were aligned using a CLUSTAL W program [20]. The mean numbers of synonymous substitutions per synonymous site (d_S) and nonsynonymous substitutions per nonsynonymous site (d_N) and their standard errors were computed using the Nei and Gojobori method [21], with the Jukes and Cantor correction, implemented in MEGA4.0 [22]. The statistical difference between d_S and d_N was tested using a one-tailed Z-test with 500 bootstrap pseudo samples using MEGA. A value of d_N significantly higher than d_S at the 95% confidence level was taken as evidence for positive selection. When the number of synonymous (Sd) or nonsynonymous (Nd) differences were less than 10, Fisher's exact test was used to estimate the significant difference. Nucleotide diversity (π) was computed using DnaSP5.0 [23]. Sliding window plots of the nucleotide diversity (90 bases with a step size of 3 bases) was computed using DnaSP5.0. Images of the sliding window plot results were generated using Excel software and modified using Adobe Photoshop. Nucleotide and amino acid (aa) positions are after 3D7 line sequence.

Tajima's D test was used to evaluate a departure from the neutral evolution model by comparing θ (nucleotide diversity estimated based on the number of segregating site, S) and π (observed pairwise nucleotide diversity) to investigate whether polymorphic single nucleotide alleles tend to occur at higher or lower frequency than expectation under neutral drift [24]. Fu and Li's D^* and F^* tests evaluate departures from neutrality by comparing the number of mutations in the external (considered to be "new" mutations) and internal (considered to be "older" mutations) branches of the genealogy. The number of external mutations would be deviated from neutral expectation by the selective pressure, whereas the number of internal mutations is less affected. Under positive balancing selection, the number of internal "old" mutations is expected to be higher than the number of external "new" mutations. Fu and Li's D^* compares the estimated θ based on the number of singletons (mutations appearing only once among the sequences, which is new and locates in the external branches) and that based on S . Fu and Li's F^* compares the estimated θ based on the number of singletons and that based on k (average number of pairwise nucleotide difference) [25]. These tests were executed using DnaSP5.0.


Results

Polymorphism of the *surf*_{4.1} gene and its product in the western Kenyan *P. falciparum* population

Twenty-four nucleotide sequences (nt 4–2289) encoding the extracellular region of SURFIN_{4.1} were obtained from western Kenyan field isolates in this study. A total of 410 polymorphic nucleotide sites were observed with an average pairwise nucleotide diversity of 0.048. All insertions/deletions (indels; AAT at nt 1348–1350, TAC at 1746–1748, GGA at 2272–2274) found in previously reported Thai *surf*_{4.1} sequences were also detected in western Kenyan isolates. To evaluate the regions accumulating the polymorphisms, the extracellular region of SURFIN_{4.1} was divided into 4 regions based on amino acid sequence conservation among SURFIN members: N-terminal segment (Nter; aa 1–50, nt 1–150), Cys-rich domain (CRD; aa 51–195, nt 151–585), a variable region 1 (Var1; aa 196–502, nt 586–1506), and –2 (Var2; aa 503–765, nt 1507–2289) as described previously [17]. The polymorphic sites were mainly distributed in the variable region; 398 among 410 polymorphic nucleotide sites were located in the variable region and 11.7% of 918 nucleotides consisting Var1 region and 37.2% of 783 nucleotides consisting of Var2 region were polymorphic (Table 2). The degree of the polymorphism was enhanced at amino acid level; 26.0% of 307 amino acids consisting of Var1 and 66.6% of 261 amino acids consisting of Var2 were polymorphic. Sliding window plots of nucleotide diversity and amino acid polymorphism indicated that in the Var2 region more polymorphism accumulated toward the C-terminal side as similar as the previous finding for Thai parasite population (Fig. 2) [17].

Selection on the *surf*_{4.1} gene in the western Kenyan *P. falciparum* population

The signatures of selection on *surf*_{4.1} were first evaluated in the western Kenyan parasite population by comparing d_S and d_N (Table 1). Significant excess of d_N over d_S was observed when the entire sequence or only Var2 region were analysed ($p = 0.004$ and 0.0003 , respectively). No significant difference between d_N and d_S was found in Nter, CRD, and Var1 regions (Fisher's exact test). To visualize the sites where the excess of d_N over d_S is observed and compare the pattern among 3 different geographical locations, the sliding window plots of d_N/d_S calculated for the *surf*_{4.1} gene sequences previously reported from the eastern Kenyan ($n = 51$) and Thai ($n = 37$) *P. falciparum* populations were overlaid in Fig. 3 [15, 17]. All three populations showed a similar pattern and two Kenyan populations showed a significant excess of d_N over d_S at the Var1 C-terminus and almost entire Var2 region ($p < 0.05$).



No significant deviation from the neutrality was detected by 3 population-based tests when the entire obtained sequence was analysed, or the 4 subdivided regions were analysed separately (Table 2). To analyse further the region where the potential balancing/directional selection act on the *surf_{4.1}* gene and compare among 3 different geographical locations, the sliding window plots of Tajima’s *D*, Fu and Li’s *D*^{*}, and *F*^{*} calculated for *surf_{4.1}* gene sequences previously reported from the eastern Kenyan and Thai *P. falciparum* populations were overlaid in Fig. 4. All 3 population-based tests showed similar patterns between western and eastern Kenyan populations and revealed a significant positive deviation of greater than zero at the Var2 C-terminus ($p < 0.05$) in the western Kenyan population, where Thai population also showed significant positive Fu and Li’s *D*^{*}, and *F*^{*} values and not significant but positive Tajima’s *D* value ($0.05 \leq p < 0.1$) [17]. This region was not sequenced for the eastern Kenyan population, thereby not examined in the previous report [15]. Thus, both Kenyan and Thai populations consistently showed positive deviation on

the Var2 C-terminus. Tajima’s test also detected significant positive deviation on CRD region ($p < 0.05$, Fig. 4 asterisk) in the western Kenyan population, where not significant but positive values are similarly seen in both eastern Kenyan and Thai populations ($p \geq 0.1$). In addition, significant negative deviation was detected on the C-terminal half of the Var1 region ($p < 0.05$, Fig. 4 hashes), where significant negative deviation was also detected in the eastern Kenyan population [15], but positive selection was detected in the Thai population. Significant negative deviation observed in the region encoding the very C-terminal side of Var1 to N-terminal of Var2 region in the eastern Kenyan population (Fig. 4 dagger) was not seen in the western Kenyan population.


To understand the difference in the selection detected on the *surf_{4.1}* gene locus between Kenyan and Thai *P. falciparum* populations, the pattern and frequency distribution of the polymorphic amino acid sites were visualized in these populations (Fig. 5). Both Kenyan populations (eastern Kenya, 1998, reported previously [15] and western Kenya, 2014, obtained in this study) had similar distribution of

Table 1 Nucleotide diversity of *Plasmodium falciparum surf_{4.1}* in western Kenyan isolates (n = 24)

Region (position)	Number of sites (base)	Indels	k (SE)	Nd (SE)	N (SE)	Sd (SE)	S (SE)	π (SE)	d_N (SE)	d_S (SE)	d_N/d_S	<i>p</i> ($d_N > d_S$)
Extracellular (4–2289)	2286	9	104.64 (5.50)	87.22 (6.03)	1791.60 (8.40)	17.43 (2.25)	488.40 (8.40)	0.048 (0.003)	0.051 (0.003)	0.037 (0.005)	1.38	0.004
Nter (4–150)	147	0	0.24 (0.19)	0.24 (0.17)	118.30 (2.01)	0.00 (0.00)	28.70 (2.10)	0.002 (0.001)	0.002 (0.002)	0.000 (0.000)	∞	ns*
CRD (151–585)	435	0	2.99 (1.11)	1.52 (0.70)	351.61 (3.68)	1.47 (0.79)	80.39 (3.64)	0.007 (0.003)	0.004 (0.002)	0.019 (0.011)	0.21	ns*
Var1 (586–1506)	918	3	20.23 (2.15)	17.86 (2.16)	721.42 (5.52)	2.37 (0.64)	196.58 (5.57)	0.023 (0.002)	0.026 (0.003)	0.012 (0.003)	2.17	ns*
Var2 (1507–2289)	783	6	81.19 (4.73)	67.60 (4.62)	600.28 (4.74)	13.59 (1.97)	182.72 (4.57)	0.115 (0.007)	0.126 (0.009)	0.080 (0.011)	1.58	0.0003

Extracellular, extracellular region; Nter, N-terminal segment; CRD, cysteine-rich domain; Var1, variable region 1; Var2, variable region 2; sites, sites nucleotide analyzed; indels, insertion/deletion polymorphism; k, the average number of nucleotide differences; N and S, average numbers of nonsynonymous and synonymous sites; π , pairwise nucleotide diversity (Jukes-Cantor model); d_N , mean number of nonsynonymous substitutions per nonsynonymous site; d_S , mean number of synonymous substitutions per synonymous site; SE, standard error computed using the Nei-Gojobori method with the Jukes-Cantor correction. SE was estimated using the bootstrap method with 500 replication

The numbers of synonymous (*Sd*) and nonsynonymous (*Nd*) differences were calculated by the Nei-Gojobori method. *p* value indicates the statistical difference between d_N and d_S , tested using one-tail Z-test with 500 bootstrap pseudo samples implemented in MEGA. ns indicates not significant by two-tailed Fisher’s exact tests (*). Number is after 3D7 line sequence



polymorphic amino acid sites suggesting that the pattern is spatially and temporally stable between these two areas in Kenya. When the frequency of the minor allele at 181 dimorphic amino acid sites were compared, it is evident that Kenyan populations possess less dimorphic amino acid sites at intermediate frequency whereas the Thai population (1988–1989, reported previously [17]) were skewed towards more frequent intermediate alleles.

Frequency of the frameshift mutation that would result no SURFIN_{4.1} expression on the iRBC surface varies between western Kenyan and Thai parasite populations

Frameshift mutations influence the expression of SURFIN_{4.1} on the surface of iRBC, potentially impacting evolutionary dynamics. To infer on this possibility, the frequency of the frameshift mutations was examined at nt 2498–2503, 3894–3903, and 4529–4536 in *P. falciparum* lines isolated from western Kenya and Thailand (Fig. 1; Table 3). No parasite line showed a frameshift at nt 4529–4536. Twenty-two among 23 western Kenyan parasite lines (96%) and 22 among 36 Thai parasite lines (61%) possessed a frameshift at nt 2498–2503 that would produce SURFIN_{4.1} without cytoplasmic WR domains. No western Kenyan, but one Thai parasite line possessed a frameshift at nt 3894–3903 that would produce SURFIN_{4.1} with single WR domain. Hence, one western Kenyan and 13 Thai lines did not possess frameshifts at the examined 3 sites as observed in IT line sequence and possibly express SURFIN_{4.1} with 3 intact WR domains. Therefore, only 1 among 23 western Kenyan parasites (4%) and 14 among 36 Thai parasites (39%), are expected to possess SURFIN_{4.1} with at least one cytoplasmic WR domain.

To gain insight if these frameshifts are common in the giant ape malaria parasites close to *P. falciparum* [26], *surf_{4.1}* gene sequence (PRCDC_0005300, GeneDB) of the CDC line of Chimpanzee malaria parasite *Plasmodium reichenowi* was examined. It was found that *P. reichenowi surf_{4.1}* sequence did not possess these frameshifts even though only one sequence was examined, suggesting that at least an intact *surf_{4.1}* gene without frameshifts existed in the common ancestor of *P. falciparum* and *P. reichenowi* and likely not rare.

surf_{4.1} CNV is common in the western Kenyan P. falciparum population, but not in Thai population


Recent genome-wide analysis of the *P. falciparum* CNVs suggested that CNVs were targets of the purifying selection and particular CNVs found at high frequencies in

Table 2 Test of neutrality for *Plasmodium falciparum surf_{4.1}* for the western Kenyan isolates (n = 24)

Region	Nucleotide position	Number of sites (base)	η	S	Two variants		More than two variants	π	θ	Tajima's D	Fu and Li's	
					Singleton	Not singleton					D*	F*
Extracellular	4–2289	2286	439	410	115	266	29	0.046	0.048	−0.19	−0.29	−0.30
Nter	4–150	147	2	2	1	1	0	0.002	0.004	−1.20	−0.66	−0.93
CRD	151–585	435	11	10	3	6	1	0.007	0.006	0.39	−0.61	−0.36
Var1	586–1506	918	109	107	44	61	2	0.022	0.031	−1.17	−0.93	−1.18
Var2	1507–2289	783	317	291	67	198	26	0.104	0.100	0.17	−0.02	0.05

Sequence number is after 3D7 line sequence


Extracellular, extracellular region; Nter, N-terminal segment; CRD, cysteine-rich domain; Var1, variable region 1; Var2, variable region 2; sites, nucleotide sites analyzed; η, the total number of mutations; S, number of segregating sites; π, observed nucleotide diversity; θ, the expected nucleotide diversity under neutrality derived from S




populations with a large effective population size (such as Africa) were likely beneficial [27]. Because CNV has been reported for $surf_{4.1}$, the copy number was examined in western Kenyan and Thai isolates. More than one copy of $surf_{4.1}$ gene was detected in western Kenya lines (17%, 3/24 showed two copies and 1/24 showed three copies), but not in Thai lines (0%, 0/36). This suggests that even though the cytoplasmic WR domain was not expressed, $surf_{4.1}$ CNV appears to be positively selected in Africa. As a control, 3D7 and FCR3 lines were examined and single and three copies were detected, respectively. Although Mphande et al. detected 6 copies of $surf_{4.1}$ in FCR3, CNVs is known to rapidly change during the in vitro culture, so this may be due to the different culture history of FCR3 [3].

Discussion

In this study, *P. falciparum* field isolates were collected from patients in western Kenya, adapted to in vitro culture, and 24 sequences encoding SURFIN $_{4.1}$ extracellular region were determined. Despite the previous report describing only negative selection on $surf_{4.1}$ in the eastern Kenyan parasite population [15], positive balancing selection was detected on this gene in the western





Kenyan population. The highest positive deviation by all neutrality tests were detected on the stretch encoding a region close to the transmembrane region (nt 2108–2254 by Tajima's test, nt 2129–2248 by Fu and Li's *D** test, and nt 2117–2263 by Fu and Li's *F** test). Because Ochola et al. [15] analysed *surf*_{4.1} sequences spanning only nt 61–2124, the most polymorphic region was not fully covered by their analysis, explaining the failure to detect positive selection. It was inferred that the Var2 C-terminus is under immunological selection pressure in both Kenyan and Thai populations.

Negative values were detected on the *surf*_{4.1} gene encoding Var1 C-terminus by population-based analyses in the western Kenyan parasite population, which were also detected for eastern Kenyan population and inferred to be a reflection of directional selection [15]. However, positive values were detected for this region in Thai population [17]. To seek possible explanation for this discrepancy, the study examined frameshifts in the cytoplasmic region that cause a *surf*_{4.1} product having only 19 aa cytoplasmic tail without WR domain, which is implicated to be responsible for the iRBC surface exposure. Ninety-six percent of Kenyan *P. falciparum* lines possessed this frameshift mutation and were expected to be exposed to the host immunity only on the merozoite surface. If SURFIN_{4.1} exposed on the iRBCs is involved with the adherence to the endothelial cells or uninfected RBCs, the frequency of the observed alleles is a result of a balance between pressures to increase the alleles with most

fitted specificity and strength to recognize the receptor and the other pressure to escape from the host immunity. Because Var1 region may participate to form a homomeric complex [4], dominant alleles in Kenya may have a better fitness to function on the merozoite surface.

Based on the finding in this study, the authors propose the following model for the *surf*_{4.1} gene evolution in Kenya and Thailand (Fig. 6). Ancestor of *surf*_{4.1} gene with intact full length of open reading frame was originally formed in *Laverania Plasmodium* infecting giant apes in Africa [26], as suggested by the sequence of the *P. reichenowi surf*_{4.1} ortholog without frameshift mutations. After the introduction of the ancestral *P. falciparum* to human population, most of the currently observed *surf*_{4.1} polymorphism was shaped under the diversifying selection in Africa, which is suggested by the significant excess of *d*_N over *d*_S and the conserved polymorphism between Kenyan and Thai parasite isolates. It should be noted that the polymorphism of SURFIN_{4.1} is more abundant than that of SURFIN_{4.2} that is still expressed on the iRBC, suggesting stronger immune pressure to SURFIN_{4.1} [17]. Frameshift mutation that results in truncated SURFIN_{4.1} expressed on the merozoite surface but not on the iRBC emerged and expanded in Africa. Although the cause of increased frequency of this frameshift mutation in the *P. falciparum* population is unclear, a loss-of-function of SURFIN_{4.1} on the iRBC surface (such as a deficient mutant of the host receptor) followed by immunity against non/less-functional SURFIN_{4.1} would favour this

Table 3 Existence of frameshift mutations in the *surf*_{4.1} region encoding the cytoplasmic region in the western Kenyan and Thai *Plasmodium falciparum* isolates

	Frameshift (nucleotide positions ^a)			Number (%) of parasite line/clone ^b			
	2498–2503	3894–3903	4529–4536	Western Kenya		Thai	
Pattern 1	Yes	Yes	No	8	(35)	17	(47)
Pattern 2	Yes	No	No	14	(61)	5	(14)
Pattern 3	No	Yes	No	0	(0)	1	(3)
Pattern 4	No	No	No	1	(4)	13	(36)
Total				23	(100)	36	(100)
3D7 ^c	Yes	Yes	No				
FCR3 ^c	No	No	Yes				
IT ^d	No	No	No				
PrCDC ^d	No	No	No				

^a Nucleotide positions are after 3D7 line sequence

^b Pattern 1 contains KK14-92-B7, KN14-098-D1, KT14-111-H2, KU14-044-D2, KU14-050-B3, KU14-071-D4, KU14-226-G5, KU14-257-A7, MS804, MS807-H3, MS836, MS808, MS812, MS828, MS827, MS838, MS830, MS814-F1, MS814-H1, MS815-A2, MS818-C2, MS833-B4, MS840, MS841, and MS829-B5; pattern 2 contains KK14-02-B9, KK14-53-F6, KN14-076-B6, KT14-158-G3, KU14-042-D12, KU14-061-B1, KU14-062-A8, KU14-110-C4, KU14-119-D4, KU14-127-B12, KU14-170-A10, KU14-175-D6, KU14-211-D1, KU14-217-B5, MS811, MS813, MS835A1, MS844-A4, and MS947; pattern 3 contains MS843; and pattern 4 contains KU14-086-B3, MS805, MS806, MS809, MS810, MS816, MS817, MS819-A3, MS822-G8, MS825, MS837, MS842, MS946, and MS948

^c GenBank accession numbers for 3D7 and FCR3 lines are AL844503 and AB759920, respectively

^d PFIT_0400900 and PRCDC_0005300 from GeneDB, Wellcome Trust Sanger Institute, UK (both are 2015-06-18 version)




Fig. 6 Proposed model for the evolution of the *surf*_{4.1} gene locus. Nucleotide (nt) positions are after 3D7 line sequence. CNV copy number variation, iRBC infected red blood cell, WR Trp-rich domain

frameshift mutation. Such a hypothesis is plausible as it is known that some human molecules were evolved to escape from the parasite recognition, for example majority of west Africans do not express the Duffy Antigen

Receptor for Chemokines (DARC), a receptor for the other human malaria parasite *Plasmodium vivax*, on their RBC and became resistant against this malaria parasite species [28, 29]. Acquiring a role only on the

merozoite surface, fitted SURFIN_{4.1} alleles might have been selected in Africa under directional selection. CNVs would be beneficial under such situation. In Thailand, it is not clear if the frequency of this frameshift mutation was increased, maintained, or decreased to ~60% after the *P. falciparum* migration to Asia, and also if the frequency is still increasing toward the level in Africa (~95%). The transmission intensity in Southeast Asia is much lower than Africa, reducing the chance to mate and produce novel haplotypes, which may influence the speed to change the frequency of particular alleles that fit to the new environment. However, because *P. falciparum* was speculated to migrate to Asia with humans around ~50,000–60,000 years ago [30], the intermediate frequency of this frameshift mutation observed in Thailand may be already adapted to the local environment. If this is the case, the hypothetical SURFIN_{4.1} receptor may be still expressed in the Asian human population. Nonetheless, more studies are needed to understand the background of this complex genetic signature, especially identification of the hypothetical SURFIN_{4.1} receptor would provide a critical answer to this question.

Conclusions

Signatures of diversifying and balancing selections were detected on the *surf*_{4.1} region encoding SURFIN_{4.1} Var2 C-terminus in western Kenyan *P. falciparum* population similar to Thai parasite population [17]. Whereas, signature of directional selection was detected on the region encoding SURFIN_{4.1} Var1 C-terminus in the western Kenyan population, consistent to the previous report for the eastern Kenyan population [15]. Most western Kenyan isolates possess a frameshift mutation that would limit the expression of SURFIN_{4.1} on the merozoite, but only ~60% of Thai isolates possess this frameshift, which would significantly affect the level and type of the selection pressure against this protein. CNV was observed in 4/24 Kenya isolates and 0/36 Thai isolates, which may be a consequence of this frameshift mutation and to increase expression on the merozoite surface.

Abbreviations

aa: amino acid position; CNV: copy number variation; DNA: deoxyribo nucleic acid; indels: insertions/deletions; nt: nucleotide position; PCR: polymerase chain reaction; *surf* gene: surface-associated interspersed gene.

Authors' contributions

JG, AK, and OK conceived and designed the experiments. JG, MK, ZMI, CWC, JK, FM, YI, AK, and OK participated to isolate *P. falciparum*. JG, MT and KY participated to adapt parasites to in vitro culture. JG and MT performed molecular experiments. JG and OK analysed the data and wrote the manuscript. All authors read and approved the final manuscript.

Author details

¹ Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. ² Department of Protozoology, Institute

of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. ³ Department of Clinical Medicine, Mount Kenya University, PO Box 342-01000, Thika, Kenya. ⁴ Radioisotope Centre, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. ⁵ Island Malaria Group, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Nobels väg 16, SE 171 77 Stockholm, Sweden. ⁶ Department of Parasitology and Medical Entomology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, 56000 Kuala Lumpur, Malaysia. ⁷ Nairobi Research Station, Nagasaki University Institute of Tropical Medicine-Kenya Medical Research Institute (NUITM-KEMRI) Project, Institute of Tropical Medicine (NEKKEN), Nagasaki University, P. O. Box 19993-00202, Nairobi, Kenya. ⁸ Department of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. ⁹ Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.

Acknowledgements

We are grateful to R. Tanaka and S. Takahama for their expertise. Human RBCs and plasma were obtained from the Nagasaki Red Cross Blood Center. This study was conducted at the Joint Usage/Research Center on Tropical Disease, Institute of Tropical Medicine, Nagasaki University, Japan. *surf*_{4.1} sequence of *P. falciparum* IT line and *P. reichenowi* CDC line were obtained from GeneDB, Wellcome Trust Sanger Institute, UK (2015-06-18 version) through PlasmoDB.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Data presented in this paper will be provided upon reasonable request. Sequence data presented are deposited to DDBJ/EMBL/GenBank™ under Accession Numbers; KU358951–KU358974.

Ethics approval and consent to participate

The study was reviewed and approved by the Kenyatta National Hospital-University of Nairobi Ethics Approval Committee (Protocol Number P9/01/2012) and was conducted in compliance with all relevant ethical standards and regulations governing research involving human subjects.

Funding

This work was supported in part by Grants-in-Aids for Scientific 24406012 (OK) and 26257504 (AK) and for Scientific Research on Innovative Areas 23117008 (OK), MEXT, Japan and Japan Society for Promotion of Science Core-to-Core Program, B. Asia-Africa Science Platforms (AK), Japan. JG is a recipient of the JSPS RONPAKU program scholarship (KEN-11303).

Received: 30 December 2016 Accepted: 20 February 2017

Published online: 02 March 2017

References

1. WHO. World Malaria Report. Geneva: World Health Organization; 2015.
2. Winter G, Kawai S, Haeggström M, Kaneko O, von Euler A, Kawazu S, et al. SURFIN is a polymorphic antigen expressed on *Plasmodium falciparum* merozoites and infected erythrocytes. *J Exp Med*. 2005;201:1853–63.
3. Mphande FA, Ribacke U, Kaneko O, Kironde F, Winter G, Wahlgren M. SURFIN_{4.1}, a schizont-merozoite associated protein in the SURFIN family of *Plasmodium falciparum*. *Malar J*. 2008;7:116.
4. Zhu X, Yahata K, Alexandre JS, Tsuboi T, Kaneko O. The N-terminal segment of *Plasmodium falciparum* SURFIN_{4.1} is required for its trafficking to the red blood cell cytosol through the endoplasmic reticulum. *Parasitol Int*. 2013;62:215–29.
5. Kagaya W, Miyazaki S, Yahata K, Ohta N, Kaneko O. The cytoplasmic region of *Plasmodium falciparum* SURFIN_{4.2} is required for transport from Maurer's clefts to the red blood cell surface. *Trop Med Health*. 2015;43:265–72.
6. Conway DJ, Polley SD. Measuring immune selection. *Parasitology*. 2002;125:S3–16.

7. Polley SD, Conway DJ. Strong diversifying selection on domains of the *Plasmodium falciparum* apical membrane antigen 1 gene. *Genetics*. 2001;158:1505–12.
8. Cortés A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for *Plasmodium falciparum* vaccine candidate AMA1. *Infect Immun*. 2003;71:1416–26.
9. Polley SD, Chokejindachai W, Conway DJ. Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. *Genetics*. 2003;165:555–61.
10. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. *Nat Med*. 2000;6:689–92.
11. Conway DJ. Natural selection on polymorphic malaria antigens and the search for a vaccine. *Parasitol Today*. 1997;13:26–9.
12. Ferreira MU, Hartl DL. *Plasmodium falciparum*: worldwide sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-2 (MSP-2). *Exp Parasitol*. 2007;115:32–40.
13. Polley SD, Tetteh KK, Lloyd JM, Akpogheneta OJ. *Plasmodium falciparum* merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. *J Infect Dis*. 2007;195:279–87.
14. Baum J, Thomas AW, Conway DJ. Evidence for diversifying selection on erythrocyte-binding antigens of *Plasmodium falciparum* and *P. vivax*. *Genetics*. 2003;163:1327–36.
15. Ochola LI, Tetteh KK, Stewart LB, Riitho V, Marsh K, Conway DJ. Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in *Plasmodium falciparum*. *Mol Biol Evol*. 2010;27:2344–51.
16. Kaewthamasorn M, Yahata K, Alexandre JS, Xangsayarath P, Nakazawa S, Torii M, et al. Stable allele frequency distribution of the polymorphic region of SURFIN_{4.2} in *Plasmodium falciparum* isolates from Thailand. *Parasitol Int*. 2012;61:317–23.
17. Xangsayarath P, Kaewthamasorn M, Yahata K, Nakazawa S, Sattabongkot J, Udomsangpetch R, et al. Positive diversifying selection on the *Plasmodium falciparum* *surf_{4.1}* gene in Thailand. *Trop Med Health*. 2012;40:79–89.
18. Idris ZM, Chan CW, Kongere J, Gitaka J, Logedi J, Omar A, et al. High and heterogeneous prevalence of asymptomatic and sub-microscopic malaria infections on islands in Lake Victoria, Kenya. *Sci Rep*. 2016;6:36958.
19. Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science*. 1976;193:673–5.
20. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. *Nucleic Acids Res*. 1994;22:4673–80.
21. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. *Mol Biol Evol*. 1986;3:418–26.
22. Tamura K, Stecher G, Peterson D, Filipiński A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*. 2013;30:2725–9.
23. Rozas J, Sánchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. *Bioinformatics*. 2003;19:2496–7.
24. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. *Genetics*. 1989;123:585–95.
25. Fu YX, Li WH. Statistical tests of neutrality of mutations. *Genetics*. 1993;133:693–709.
26. Liu W, Sundararaman SA, Loy DE, Learn GH, Li Y, Plenderleith LJ, et al. Multigenomic delineation of *Plasmodium* species of the *Laverania* subgenus infecting wild-living chimpanzees and gorillas. *Genome Biol Evol*. 2016;8:1929–39.
27. Cheeseman IH, Miller B, Tan JC, Tan A, Nair S, Nkhoma SC, et al. Population structure shapes copy number variation in malaria parasites. *Mol Biol Evol*. 2016;33:603–20.
28. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med*. 1976;295:302–4.
29. Liu W, Li Y, Shaw KS, Learn GH, Plenderleith LJ, Malenke JA, et al. African origin of the malaria parasite *Plasmodium vivax*. *Nat Commun*. 2014;5:3346.
30. Tanabe K, Mita T, Jombart T, Eriksson A, Horibe S, Palacpac N, et al. *Plasmodium falciparum* accompanied the human expansion out of Africa. *Curr Biol*. 2010;20:1283–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

